For stage III unresectable NSCLC, consolidation immunotherapy targeting PD-L1 has become a new standard of care in patients without disease progression after concurrent platinum-based chemo-radiotherapy (PACIFIC regimen). Here, CD274 is linked to non-small cell lung carcinoma.